A Clinical Study in AGHD to Assess Safety, Tolerability and Efficacy of GX-H9

Summary

This is a randomized, active-controlled, open-label, sequential dose group, Phase 1b/2 study designed to assess the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of weekly and every other week doses of GX-H9 in the treatment of AGHD.

Timeline

Start

2015-01

Primary completion

2016-12-30

Completion

2016-12-30

Drugs

Indications